Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

A Human Immortalized Cell-Based Blood-Brain Barrier Triculture Model: Development and Characterization as a Promising Tool for Drug-Brain Permeability Studies.

Ito R, Umehara K, Suzuki S, Kitamura K, Nunoya KI, Yamaura Y, Imawaka H, Izumi S, Wakayama N, Komori T, Anzai N, Akita H, Furihata T.

Mol Pharm. 2019 Nov 4;16(11):4461-4471. doi: 10.1021/acs.molpharmaceut.9b00519. Epub 2019 Oct 15.

PMID:
31573814
2.
3.

Unique Hydrolysis of an Ester-Type Prodrug of Levodopa in Human Plasma: Relay-Type Role Sharing between Alpha-1 Acid Glycoprotein and Human Serum Albumin.

Kono K, Fukuchi Y, Okawa H, Nunoya KI, Imawaka H, Watanabe H, Maruyama T.

Mol Pharm. 2019 Oct 7;16(10):4131-4138. doi: 10.1021/acs.molpharmaceut.9b00435. Epub 2019 Aug 28.

PMID:
31433646
4.

Expanded Physiologically-Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction.

Asaumi R, Menzel K, Lee W, Nunoya KI, Imawaka H, Kusuhara H, Sugiyama Y.

CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):845-857. doi: 10.1002/psp4.12457. Epub 2019 Sep 5.

5.

Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug-Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects.

Asaumi R, Toshimoto K, Tobe Y, Hashizume K, Nunoya KI, Imawaka H, Lee W, Sugiyama Y.

CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):186-196. doi: 10.1002/psp4.12275. Epub 2018 Feb 5.

6.

Sandwich-Cultured Hepatocytes for Mechanistic Understanding of Hepatic Disposition of Parent Drugs and Metabolites by Transporter-Enzyme Interplay.

Matsunaga N, Fukuchi Y, Imawaka H, Tamai I.

Drug Metab Dispos. 2018 May;46(5):680-691. doi: 10.1124/dmd.117.079236. Epub 2018 Jan 19.

PMID:
29352067
7.

Analysis of Nonlinear Pharmacokinetics of a Highly Albumin-Bound Compound: Contribution of Albumin-Mediated Hepatic Uptake Mechanism.

Fukuchi Y, Toshimoto K, Mori T, Kakimoto K, Tobe Y, Sawada T, Asaumi R, Iwata T, Hashimoto Y, Nunoya KI, Imawaka H, Miyauchi S, Sugiyam Y.

J Pharm Sci. 2017 Sep;106(9):2704-2714. doi: 10.1016/j.xphs.2017.04.052. Epub 2017 Apr 30.

PMID:
28465151
8.

Analysis of the Metabolic Pathway of Bosentan and of the Cytotoxicity of Bosentan Metabolites Based on a Quantitative Modeling of Metabolism and Transport in Sandwich-Cultured Human Hepatocytes.

Matsunaga N, Kaneko N, Staub AY, Nakanishi T, Nunoya K, Imawaka H, Tamai I.

Drug Metab Dispos. 2016 Jan;44(1):16-27. doi: 10.1124/dmd.115.067074. Epub 2015 Oct 26.

PMID:
26502773
9.

Modeling approach for multiple transporters-mediated drug-drug interactions in sandwich-cultured human hepatocytes: effect of cyclosporin A on hepatic disposition of mycophenolic acid phenyl-glucuronide.

Matsunaga N, Suzuki K, Nakanishi T, Ogawa M, Imawaka H, Tamai I.

Drug Metab Pharmacokinet. 2015 Apr;30(2):142-8. doi: 10.1016/j.dmpk.2014.10.006. Epub 2014 Nov 14.

PMID:
25989889
10.

Inclusion of human intravenous study data in new drug applications-impact of the Japanese guidance.

Imawaka H, Kusama M, Ito K, Ono S, Sugiyama Y.

J Pharm Sci. 2012 Jul;101(7):2557-63. doi: 10.1002/jps.23135. Epub 2012 Apr 12.

PMID:
22499211
11.

Prediction of human bioavailability from human oral administration data and animal pharmacokinetic data without data from intravenous administration of drugs in humans.

Imawaka H, Ito K, Kitamura Y, Sugiyama K, Sugiyama Y.

Pharm Res. 2009 Aug;26(8):1881-9. doi: 10.1007/s11095-009-9902-6. Epub 2009 May 7.

PMID:
19418207
12.

The effect of continuous arterial infusion of gabexate mesilate (FOY-007) on experimental acute pancreatitis.

Satoh H, Harada M, Tashiro S, Shiroya T, Imawaka H, Machii K.

J Med Invest. 2004 Aug;51(3-4):186-93.

13.

Design and synthesis of new orally active inhibitors of human neutrophil elastase.

Ohmoto K, Okuma M, Yamamoto T, Kijima H, Sekioka T, Kitagawa K, Yamamoto S, Tanaka K, Kawabata K, Sakata A, Imawaka H, Nakai H, Toda M.

Bioorg Med Chem. 2001 May;9(5):1307-23.

PMID:
11377188
14.

Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist.

Imawaka H, Sugiyama Y.

J Pharmacol Exp Ther. 1998 Mar;284(3):949-57.

PMID:
9495854
15.

Anti-thrombotic effect of ONO-8809, a novel TXA2/PG endoperoxide receptor antagonist.

Wakitani K, Matsumoto R, Imawaka H, Kamanaka Y, Naka M, Hamanaka N, Okegawa T, Kawasaki A.

Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:599-602. No abstract available.

PMID:
1825384
16.

Effects of ONO-3708, an antagonist of the thromboxane A2/prostaglandin endoperoxide receptor, on blood vessels.

Kondo K, Seo R, Omawari N, Imawaka H, Wakitani K, Kira H, Okegawa T, Kawasaki A.

Eur J Pharmacol. 1989 Sep 13;168(2):193-200.

PMID:
2606148

Supplemental Content

Loading ...
Support Center